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Abstract 21 
 22 
Background: Previous results obtained from serum samples of late-stage, high-grade serous ovarian 23 
carcinoma patients showed large alterations in lipid metabolism. To validate and extend the results, 24 
we studied lipidomic changes in early-stage ovarian tumors. In addition to serous ovarian cancer, we 25 
investigated whether these changes occur in mucinous and endometrioid histological subtypes as 26 
well.  27 
Methods: Altogether, 354 serum or plasma samples were collected from three centers, one from 28 
Germany and two from Finland. We performed lipidomic analysis of samples from patients with 29 
malignant (N=138) or borderline (N=25) ovarian tumors, and 191 controls with benign pathology. 30 
These results were compared to previously published data.  31 
Results: We found 39 lipids that showed consistent alteration both in early- and late-stage ovarian 32 
cancer patients as well as in pre- and postmenopausal women. Most of these changes were already 33 
significant at an early stage and progressed with increasing stage. Furthermore, 23 lipids showed 34 
similar alterations in all investigated histological subtypes.  35 
Conclusion: Changes in lipid metabolism due to ovarian cancer occur in early-stage disease but 36 
intensify with increasing stage. These changes occur also in other histological subtypes besides high 37 
grade serous carcinoma. Understanding lipid metabolism in ovarian cancer may lead to new 38 
therapeutic and diagnostic alternatives. 39 
 40 
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Background 44 
Prognosis of ovarian cancer improves remarkably if the disease is diagnosed at an early-stage, as 45 
early detection affords better opportunities for curative treatment. Current diagnostic methods 46 
primarily include vaginal ultrasound combined with the blood test to measure cancer antigen 125 (CA 47 
125) levels. These methods lack specificity and sensitivity, especially in non-advanced ovarian 48 
cancer.1 Therefore, there is a demand for new detection methods and biomarkers for distinguishing 49 
benign and borderline ovarian tumors, as well as early-stage and advanced ovarian cancer. 50 
 51 
Malignant tumors, including ovarian cancer, adopt many metabolic abnormalities to meet the 52 
increased energy demand associated with increased cellular proliferation and tumor growth.2 In 53 
ovarian cancer, the metabolic alterations in tissues and body fluids have been investigated by 54 
metabolic profiling to identify biomarkers for early detection and reliable prognosis.3-5 Recently, 55 
using liquid chromatography-mass spectrometry (LC-MS), Gaul et al. found from serum 16 56 
diagnostic metabolites, including many lipids and fatty acids, that distinguish early-stage ovarian 57 
cancer samples from healthy control samples.6 In a lipidomic study, Buas et al. showed 34 58 
significantly altered metabolites between serous ovarian carcinoma and benign serous ovarian tumor 59 
patients, and the plasma levels of the lipids were reduced in patients with a malignant disease.7 60 
Recently, our metabolomic analyses of tumor and blood samples from high-grade serous ovarian 61 
carcinoma (HGSOC) patients showed elevated concentrations of hydroxybutyric acids, implicating 62 
that these molecules could act as diagnostic and prognostic biomarkers.8 Subsequently, lipidomic 63 
profiling of the same samples showed an overall reduction in the levels of most of the lipid species 64 
but elevations in specific ceramide (Cer) and triacylglycerol (TAG) lipids in metastatic ovarian cancer 65 
patients.9 66 
 67 
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Despite several studies showing lipidomic alterations in ovarian cancer, we are not aware of any 68 
studies that confirm which lipid species are the most consistently altered. To this end, as well as to 69 
validate our published lipidomic results and extend the analyses to low malignant potential 70 
(borderline) ovarian tumors and early-stage ovarian cancers, we applied the same previously used 71 
methodology9 to analyze blood samples from patients with early-stage ovarian cancers. These results 72 
were subsequently compared to the results obtained from patients with benign gynecological disease. 73 
Our further aim was to investigate whether the lipidomic alterations found in patients with HGSOC 74 
can be applied to other histological subtypes, i.e., to mucinous and endometrioid ovarian carcinoma.  75 
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Materials and methods 76 
Patients and samples 77 
We performed lipidomic profiling on two study cohorts, one from Charitè (N=189) and another from 78 
Finland (N=165, from Tampere (N=111) and Oulu (N=54) University Hospitals). In addition, we 79 
used data from an independent, previously published study9, referred herein as the Charité discovery 80 
(N=250). The Charité discovery study included 5 additional samples from patients with endometrioid 81 
tumors that were excluded from the original publication.9 Clinical characteristics of these three study 82 
cohorts are shown in Table 1. The samples from both Charité studies were serum samples, while the 83 
Finnish samples were a mixture of serum and plasma, as shown in Table 1. All samples were 84 
collected preoperatively. In total, in these three studies, 290 samples were collected from patients 85 
with malignant ovarian tumors, 25 samples from subjects with borderline ovarian tumors, and 289 86 
from women with benign gynecological tumors, endometriosis, infection, or other conditions. The 87 
diagnosis of invasive and borderline ovarian tumors was based on the WHO Classification.10 The 88 
gynae-pathologists at the respective hospitals (University Hospitals of Oulu and Tampere, Finland, 89 
and Charité, Berlin, Germany) did the histological analyses, and immunohistochemistry was used 90 
when needed. The Charité samples were collected at the Tumor Bank - Ovarian Cancer Network 91 
(www.toc-network.de) at the Charitè Medical University (Berlin, Germany) between 07/2013 and 92 
09/2016. The Finnish samples, from Tampere University Hospital and Oulu University Hospital, 93 
were collected between 2/2011-11/2014 and between 01/2009-12/2015, respectively.  94 
 95 
Lipidomic analysis of serum samples (LC-MS/MS) 96 
The samples were randomized within each cohort before lipidomic analysis. The lipidomic analysis 97 
has been previously described in detail.9 Briefly, lipidomic analyses were performed using two 98 
platforms, a global screening method and a phosphosphingolipid platform. For the screening method, 99 
10 µl of sample was needed for the extraction of the lipids using a modified Folch extraction.11 For 100 
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the phosphosphingolipid method, 25 µl of sample was needed for the extraction of lipids using protein 101 
precipitation in methanol.  102 
 103 
Lipidomic screening and phosphosphingolipid platforms were both analyzed on a hybrid triple 104 
quadrupole/linear ion trap mass spectrometer (QTRAP 5500, AB Sciex, Concords, Canada) equipped 105 
with ultra-high-performance liquid chromatography (UHPLC) (Nexera-X2, Shimadzu, Kyoto, 106 
Japan). Chromatographic separation of the lipidomic screening platform was performed on an 107 
Acquity BEH C18, 2.1 × 50 mm id. 1.7 µm column (Waters Corporation, Milford, MA, USA). 108 
Chromatographic separation of the phosphosphingolipid platform was performed on an AQUASIL 109 
C18, 2.1 × 50 mm, 5 µm (Thermo Fisher Scientific, Waltham, MA, USA) column set at 60 °C. For 110 
the MS analysis, a targeted approach in the positive ion mode was used for both platforms. The data 111 
were collected using a scheduled multiple reaction monitoring (sMRM™) algorithm for the 112 
lipidomics screening platform12 and multiple reaction monitoring (MRM) for phosphosphingolipids. 113 
The lipidomic data were processed using Analyst and MultiQuant 3.0 software (AB Sciex), and the 114 
area or height ratios of the analyte and its corresponding IS peak were normalized with the IS amount 115 
and the sample volume. The details of the chromatography and mass spectrometry conditions have 116 
been previously described.9 117 
 118 
The number of lipids and the mean coefficient of variation for each lipid class, determined from the 119 
quality control samples (6 in each 96-well plate), are shown in Supplementary Table S1. The list of 120 
all analyzed lipids has been published previously.9 121 
 122 
Statistical analyses 123 
Group comparisons (patients vs. controls) were performed by calculating the mean relative difference 124 
between the groups, and the p-values were determined by parametric t-tests on log-transformed 125 
concentrations. R version 3.4.2 was used for all statistical analyses. Tableau 10.1 was used for 126 
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heatmap visualizations. For diagnostic calculations, logistic regression models were developed using 127 
all samples in the Charité cohort and tested in the Finnish cohort. The AUC values were determined 128 
using the pROC package.13 The top models presented in the article were selected by calculating the 129 
sum of the AUC values in both cohorts, and selecting the models with the highest values. 130 
  131 
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Results 132 
Validation of altered lipidomic profile in ovarian cancer patients 133 
To validate the lipidomic alterations detected in ovarian cancer patients, we determined which lipids 134 
were similarly altered between the patients and the controls in the two study cohorts (Charité and 135 
Finland), in addition to the previously published Charité discovery cohort (Table 1), provided that 136 
the change between the patients and the controls was significant in at least two cohorts. The results 137 
confirmed that ovarian cancer causes wide lipidomic changes as 155 lipids showed the same direction 138 
of change in all cohorts, and most of these changes were also statistically significant in all three 139 
independent cohorts (Supplementary Table S2). All further analyses were limited to these 155 140 
lipids. 141 
 142 
Lipidomic changes emerge in early-stage ovarian cancer patients 143 
To identify which lipids have the best diagnostic potential, or those already altered in early-stage 144 
(I/II) cancer, we selected lipids that showed consistent increase or decrease both in stage I/II vs. 145 
controls and stage III/IV vs. controls, including all cohorts and histological subtypes. In addition, the 146 
lipids had to be significantly altered at least in stage III/IV patients in the Charité and Finnish cohorts. 147 
This approach resulted in 39 lipids which are shown in a heatmap in Figure 1. Samples from patients 148 
with ovarian cancer revealed a consistent decrease in the concentration of most of the analyzed lipid 149 
classes and included phospholipids (phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs) 150 
and phosphatidylinositols (PIs)), cholesteryl esters (CEs), glucosyl/galactosyl ceramides 151 
(Glc/GalCers) and sphingomyelins (SMs). In turn, an increase was observed in many ceramides 152 
(Cers) with certain fatty acyl (FA) side chain compositions. Cers with 18:0, 20:0 and 24:1 FAs were 153 
increased, while 24:0 FA-containing Cers were decreased. The TAG lipid species also showed a 154 
variable trend depending on the FA side chains; TAGs with shorter FA side chains were decreased, 155 
whereas those with longer FA side chains were increased. In many lipid species, the alterations were 156 
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more significant in advanced stage (III/IV) patients but were already present in early-stage patients 157 
(I/II) (Figure 1). The lipidomic changes were consistent in both pre- and postmenopausal patient 158 
populations (Figure 1). 159 
 160 
Tumors of various histological subtypes induce similar lipid changes 161 
As the previous results were derived from HGSOC patients only9, we investigated whether some 162 
changes in lipid species are also significant in patients with other histological subtypes (mucinous 163 
and endometrioid). Thus, we selected lipids showing the same direction of alteration in all histological 164 
subtypes of the Charité and Finnish cohorts. In addition, the selected lipids had to be significant in 165 
either mucinous or endometrioid subtypes in either of the cohorts. Twenty-one of 23 lipids were 166 
decreased in all histological subtypes (Figure 2), and only Cer(d18:1/18:0) and TAG(18:1/18:1/20:4) 167 
were increased. The most significant alterations were observed in PCs and LPCs. All lipid changes 168 
were significant in the serous subtype, which was expected based on the large number of cases in 169 
both cohorts. Interestingly, CA 125 was not significantly altered in mucinous subtype samples, while 170 
most lipid changes were significant in the Charité cohort despite a low number of mucinous cases 171 
(N=6). For endometrioid histology, none of the lipids were significant in the Charité cohort (N=9), 172 
whereas the Finnish cohort, with a slightly greater number of cases (N=14), showed significant 173 
alterations. 174 
 175 
Fewer lipid changes are seen in borderline tumors than in malignant tumors 176 
We also analyzed whether the observed lipidome alterations are present in borderline ovarian tumors. 177 
When only those lipids that were altered in the same direction in both cohorts and significant in at 178 
least one of them were selected, there were only a few significant alterations (Figure 3). Thus, it 179 
appears that borderline tumors do not cause as much of a change to the lipidome as malignant tumors. 180 
 181 
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Lipids improve the diagnostic value of CA125 for the detection of early-stage cancer 182 
Finally, we investigated whether lipids can improve the diagnostic value of CA 125. As lipid ratios 183 
have shown diagnostic value in other diseases14, we investigated combinations of all lipids and lipid 184 
ratios together with CA125. The lipids used for this analysis are shown in Figure 1. For the ratio 185 
calculations, the increased lipids in ovarian cancer patients and CA 125 were used as numerators, and 186 
all other lipids were used as denominators. To find more robust biomarkers, those lipids and lipid 187 
ratios were excluded that were significantly different (t-test p<0.05 and mean relative change > 10%) 188 
between control samples of the Charité and Finland cohorts. The models were generated using all 189 
subjects in the Charité cohort, and tested in the stage I/II and III/IV ovarian cancer patients separately, 190 
in addition to the validation in the Finnish cohort. As an example, the models with the highest 191 
improvement in both the Charité and Finnish cohorts are shown in Table 2. In the Charité cohort, CA 192 
125 as a continuous variable instead of using the 35 U/mL cut-off improved the AUC values, and 193 
further improvement was seen for the detection of early-stage cases with incorporation of lipids, but 194 
not for late-stage cases where already CA 125 alone performed well. In the Finnish cohort, which had 195 
a higher proportion of other than serous malignant tumors, the AUC values for CA 125 and also the 196 
models with lipids were lower than in the Charité, but again the lipids improved the diagnostic value 197 
of CA 125 for the detection of stage I/II cancers. 198 
 199 
  200 
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Discussion 201 
The present global lipidomics study investigating early- and advanced-stage ovarian cancer of various 202 
histological subtypes was performed to validate and extend our previous results on lipid changes in 203 
HGSOC patients. Altered lipid metabolism seems to be linked to ovarian cancer, but specific findings 204 
are still strikingly variable. Our data are in line with those earlier studies showing an overall decrease 205 
in the serum/plasma concentration of lipid metabolites7 and glycerophospholipids15,16 in ovarian 206 
cancer patients. The intensification of lipid changes in the advanced stage ovarian cancer patients 207 
suggests that the tumors are exploiting circulating lipids and lipoproteins with proportion to their size. 208 
The overall decrease of PCs may be associated with reduction of HDL cholesterol and ApoA1 in the 209 
ovarian cancer patients17,18, as PCs are known to be abundant especially in the HDL particles.19 210 
However, this phenomenon cannot be used to explain the increase of lipid species in ovarian cancer 211 
patients. It has been suggested that changes in lipid metabolism during ovarian cancer pathogenesis 212 
reflect higher levels of cell division20, enhanced fatty acid β-oxidation5, and increased cellular 213 
proliferation or motility due to increased PI3-kinase activity21, yet there are likely to be additional 214 
mechanisms explaining the alterations of specific lipids. 215 
 216 
These results confirm our previous report describing an increase in the serum concentration of 217 
Cer(d18:1/18:0), Cer(d18:0/18:0) and TAG(18:1/18:1/20:4) in ovarian cancer patients.9 Moreover, 218 
the phenomenon is evident at the early stages of disease development, i.e. stage I/II, but was found 219 
to become more pronounced with disease progression. In addition to HGSOC, Cer(d18:1/18:0) and 220 
TAG(18:1/18:1/20:4) were also significantly increased in mucinous and endometrioid ovarian cancer 221 
samples from the Finnish cohort. However, the number of mucinous and endometrioid carcinoma 222 
samples was likely too low in the Charitè cohort to show any significant difference. Interestingly, 223 
Cer(d18:1/18:0) and its precursor Cer(d18:0/18:0) have been associated with the development of 224 
insulin resistance and type 2 diabetes.22-24 Taken together, these alterations to the lipid profile and 225 
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other metabolic changes, such as increase of ketone bodies8, suggest that the metabolic profile of 226 
ovarian cancer patients resemble a diabetic phenotype. 227 
 228 
Sphingolipids, especially Cers, have been linked to the development and progression of cancer25, but 229 
results appear vary depending on the type of tumor.26 Cers are considered to have anti-cancer 230 
properties, to act as second messengers for cell apoptosis25 and to modulate cell growth.27 Another 231 
sphingolipid, sphingosine-1-phosphate (S1P), has opposing cellular effects to Cers.26 The role of 232 
sphingolipid metabolism in ovarian cancer has been investigated in a recent study in which 74 women 233 
with HGSOC were found to have significantly elevated plasma and tissue concentrations of C16-Cer, 234 
C18:1-Cer and C18-Cer compared to those of healthy controls28, which is in line with our results. 235 
The researchers speculated that the increased amounts of Cers would be associated with particularly 236 
aggressive epithelial ovarian cancer cases and that the increased Cer concentrations would lead to 237 
increased conversion to S1P, as they found an elevated S1P concentration in tumor tissue. However, 238 
congruent with our data, elevation of S1P could not be observed in blood. 239 
 240 
Buas et al. have shown reduction of all measured TAGs in the plasma of ovarian cancer patients.7 241 
However, in a lipidomic analysis of low and highly aggressive ovarian cancer cell lines, TAGs 242 
increased dramatically along aggressiveness of the cells and were assumed to be the largest source of 243 
cellular energy.29 In a mouse model of HGSOC, compared to healthy mice, the serum levels of 244 
LPE(16:0) and PIs were decreased, while TAG(55:7) was significantly increased at early-stage cancer 245 
development.30 On the other hand, decreased levels of TAGs in epithelial ovarian cancer patients 246 
have been shown to predict early recurrence of cancer.31 In our study, only the concentrations of 247 
TAGs with longer fatty acid chains were increased or not altered, while those TAGs with short fatty 248 
acid chains were decreased. Our former study proposed that this result could be explained by genetics 249 
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via low expression of the ABCD1 gene9 which is associated with transport of long-chain fatty acids 250 
into the peroxisome for β-oxidation.32 251 
 252 
Phospho- and sphingolipids are the most studied lipids in regard to the pathogenesis of ovarian 253 
cancer.33 In 2004, it was shown that plasma levels of lysophospholipids varied between healthy 254 
controls and ovarian cancer patients, as well as pre- and postoperatively.34 Moreover, in a pathway 255 
analysis, glycerophospholipid (LPCs and PCs) metabolism was a main dysregulated pathway in the 256 
pathogenesis of ovarian carcinoma.35 Alteration of LPC levels may be caused by the binding and 257 
activation of specific cell surface G protein-coupled receptors (GPCRs), which can activate cell 258 
growth and proliferation.36 Altered LPCs and lysophosphatidylethanolamines (LPEs) contribute to 259 
genetic instability and cancer initiation via enhanced phospholipase A2 (PLA2) activity37 and 260 
inflammation.3 Phospholipids are needed in cancer cells to generate the cellular membrane and 261 
maintain membrane integrity.3 A large metabolic profiling study3 of 448 plasma samples from 262 
epithelial ovarian cancer patients identified 53 specific metabolites that distinguished early- and late-263 
stage ovarian cancer with an AUC of 0.88. These metabolites included LPCs and LPEs which were 264 
elevated in localized ovarian cancer but reduced in metastasized ovarian cancer. A potential 265 
explanation for the reduced levels of LPCs and LPEs in advanced cancer could be that rapidly 266 
proliferating tumors consume more phospholipids in their attempt to maintain membrane integrity, 267 
leading to an exhaustion of substrates.30 Also lysophosphatidic acid (LPA) has been purported to be 268 
a possible biomarker because some studies have shown LPA to be elevated in plasma samples of 269 
ovarian cancer patients.34,38, but we could not confirm this as we did not monitor LPAs in our 270 
lipidomic method. 271 
 272 
Borderline ovarian tumors have low malignant potential and elevated mitotic activity without stromal 273 
invasion. They commonly occur in younger women compared to ovarian cancer patients and have 274 
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lower recurrence rates.39 Denkert et al. found significantly different metabolite levels (including 275 
metabolites from glycerolipid metabolism and free fatty acids) in borderline ovarian tumor tissues 276 
compared to invasive ovarian carcinomas using gas chromatography/time-of-flight mass 277 
spectrometry.20 However, they had only nine borderline tumors in their study. Based on the present 278 
study, lipid metabolism in borderline ovarian tumors differs from that in invasive cancers. The Charité 279 
cohort had more borderline ovarian tumors (N=18) than the Finnish cohort. These samples were 280 
mainly serous epithelial tumors. Significant differences were observed only for occasional 281 
plasmalogens as compared to benign controls. 282 
 283 
In the Charitè cohort, the results were evaluated by menopausal status. Greater alterations in Cer 284 
d16:1, d18:0 and d18:1 were observed in postmenopausal women. However, in some PC lipids, 285 
premenopausal changes were stronger. A serum lipidomics study of ovariectomized healthy rats 286 
showed that Cers and phospholipids increased in response to estrogen deficiency while TAGs 287 
decreased, which was contrary to earlier studies.40 Our study lacks data on possible hormone 288 
replacement or hormone therapy in the Charitè premenopausal group. The samples from the Finnish 289 
cohort were postmenopausal with no current hormone therapy. 290 
 291 
Our study had some limitations. First, changes in lipoprotein levels can at least partly explain the 292 
overall decrease of lipids among cancer patients, but unfortunately, we did not have lipoprotein levels 293 
available from the patients. Neither did we have the information on BMI, which may also affect lipid 294 
levels. Second, in the Finnish cohort, the sample sets contained both serum and plasma samples, 295 
which may affect the lipid levels. However, it is worth noting that the lipid changes were consistent 296 
with the two other data sets, and thus, it can be assumed that the difference does not significantly 297 
affect the results. Moreover, the logistic regression models developed in the Charité cohort showed 298 
high AUC values in the Finnish cohort, which also supports the validity of the results. Third, there 299 
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was an age imbalance in the cohorts, as the Charité cohort patients were older than the controls. 300 
However, the results were consistent with the Finnish cohort, where the controls were older than the 301 
patients. This finding and our previous age-adjusted lipidomic analyses9 suggest that age does not 302 
explain the differences in lipid metabolism observed in ovarian cancer patients. Fourth, the blood 303 
samples were not collected during a fasting condition, which may affect the results. However, it is 304 
worth noting that there were no differences between groups and that it is expected that fasting samples 305 
might have given a better separation between the ovarian cancer patients and the subjects with benign 306 
disease. 307 
 308 
We have shown that blood lipidomic changes occur in several patient cohorts and already at the early-309 
stage ovarian cancer, but intensify with the progression of the disease. Many of the lipid changes are 310 
similar in patients with serous, mucinous and endometrioid ovarian carcinoma, suggesting that 311 
rewiring of lipid metabolism is an integral part of ovarian carcinogenesis. The results provide an 312 
excellent basis for further development of diagnostics and the future investigations should also 313 
explore the potential of exploiting the altered ovarian cancer lipid metabolism for therapeutic 314 
purposes. 315 
  316 
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Figure 1. Heatmap showing lipidomic changes in early- (I/II) and late-stage (III/IV) ovarian cancer 437 
patients. In addition, the results are shown in pre- and postmenopausal patients of all stages. The 438 
difference is calculated relative to controls. The color scale (from -70% to 100%) is adjusted 439 
according to the lipids, in cancer patients CA 125 showed mean elevation higher than 100%. ***, 440 
p<0.001; **, p<0.01; *, p<0.05. Charité study had 60 premenopausal controls and 17 cancer cases as 441 
well as 48 postmenopausal controls and 42 cancer cases. 442 
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Figure 2. Heatmap showing lipidomic changes in ovarian cancer patients with different histological 444 
subtypes as compared to control subjects. The color scale (from -70% to 100%) is adjusted according 445 
to the lipids, in some of the analyses CA 125 showed elevation higher than 100%. ***, p<0.001; **, 446 
p<0.01; *, p<0.05. 447 
 448 
 449 
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Figure 3. Heatmap showing lipidomic changes in patients with borderline tumors as compared to 450 
control subjects. The color scale is adjusted according to the lipids (from -70% to 100%), CA 125 451 
showed elevation higher than 100% in the Charité cohort. ***, p<0.001; **, p<0.01; *, p<0.05. 452 
 453 
 454 
  455 
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Table 1. Clinical characteristics of the study cohorts. For age, the values represent median and interquartile 456 
range and p-values in the comparison against the control group are denoted as follows: ***, p<0.001; **, 457 
p<0.01; *, p<0.05; N.S., not significant. 458 
    Charité Finland 
Charité 
discovery 
Malignant   62 76 152 
Age  57 (50-72)*** 58 (51-64)* 59 (50-67)*** 
Histology serous 41 29 147 
  mucinous 6 18   
  endometrioid 9 14 5 
  other 6 15   
Stage I&II 26 52 8 
  III&IV 33 22 133 
  NA 3 2 11 
Sample serum 62 22 152 
  plasma  54   
Borderline   18 7   
Age  51 (44-57) 
N.S. 63 (56-67) N.S.   
Histology serous 13 5   
  mucinous 2 2   
  other 3    
Stage I&II 12 7   
  III&IV 3    
  NA 3    
Sample serum 18 7   
Benign   109 82 98 
Age  49 (40-58) 62 (56-69) 41 (31-55) 
Diagnosis other 7 2 43 
  uterine fibroid 7 1 25 
  cyst 4 9 1 
  cystic teratoma 12 8 5 
  functional cyst 22    
  inclusion cyst 3    
  endometrioid cyst 5    
  non-ovarian cyst  4   
  cystadenoma 32 2 4 
  mucinous cystadenoma  3 2 
  cystadenofibroma 7 10 2 
  serous cystadenoma  34 3 
  Brenner tumor 1 2 1 
  fibroma/thecoma  5   
  fibroadenoma  1   
  incomplete abortion   5 
  adnexitis   5 
  endometriosis 9 1 2 
Sample serum 109 82 98 
 459 
  460 
Table 2. AUC values with 95% confidence intervals for the logistic regression models. As comparison, the models are shown also for CA 125 alone or CA 461 
125 as binary variable dichotomized by the clinically used 35 U/mL cut off value. 462 
    Charité Finland 
Variable1 Variable 2 All Stage I/II Stage III/IV All Stage I/II Stage III/IV 
CA125 / Glc/GalCer(d18:1/26:0) Cer(d18:1/24:1) / LPC 14:0_sn2 0.93 (0.89-0.96) 0.87 (0.80-0.94) 0.98 (0.96-1.00) 0.76 (0.68-0.85) 0.74 (0.64-0.83) 0.93 (0.84-1.00) 
Cer(d18:1/24:1) / LPC 14:0_sn2 CA125 / PC 37:2 0.93 (0.89-0.96) 0.87 (0.81-0.94) 0.98 (0.95-1.00) 0.76 (0.68-0.85) 0.73 (0.64-0.83) 0.95 (0.89-1.00) 
Cer(d20:1/24:1) / LPC 14:0_sn2 CA125 / PC 37:2 0.92 (0.87-0.96) 0.85 (0.77-0.93) 0.98 (0.95-1.00) 0.77 (0.68-0.85) 0.74 (0.64-0.83) 0.95 (0.90-1.00) 
Cer(d18:1/24:1) / LPC 14:0_sn2 CA125 / PI 38:2 0.92 (0.89-0.96) 0.87 (0.81-0.94) 0.97 (0.94-1.00) 0.77 (0.69-0.85) 0.75 (0.66-0.84) 0.95 (0.88-1.00) 
CA125 TAG(18:1/18:1/22:6) / LPC 14:0_sn2 0.91 (0.86-0.96) 0.83 (0.73-0.92) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.89 (0.77-1.00) 
TAG(18:1/18:1/22:6) / LPC 14:0_sn2 CA125 / PC 37:2 0.91 (0.86-0.96) 0.83 (0.74-0.91) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.88 (0.73-1.00) 
TAG(18:1/18:1/22:6) / LPC 14:0_sn2 CA125 / PC P-34:2 +1 0.91 (0.86-0.96) 0.83 (0.75-0.92) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.89 (0.75-1.00) 
TAG(18:1/18:1/22:6) / LPC 14:0_sn2 CA125 / SM 37:2 0.91 (0.86-0.95) 0.83 (0.73-0.92) 0.98 (0.96-1.00) 0.78 (0.70-0.86) 0.75 (0.66-0.84) 0.91 (0.80-1.00) 
Cer(d20:1/24:1) / LPC 14:0_sn2 CA125 / PI 38:2 0.91 (0.87-0.96) 0.85 (0.76-0.93) 0.97 (0.94-1.00) 0.78 (0.70-0.86) 0.76 (0.67-0.85) 0.95 (0.88-1.00) 
TAG(18:1/18:1/22:6) / PC 30:0 CA125 / PC 30:0 0.90 (0.85-0.95) 0.82 (0.73-0.91) 0.98 (0.95-1.00) 0.79 (0.72-0.87) 0.77 (0.68-0.85) 0.91 (0.78-1.00) 
CA125   0.90 (0.84-0.95) 0.81 (0.71-0.90) 0.97 (0.94-1.00) 0.72 (0.62-0.81) 0.67 (0.57-0.78) 0.95 (0.91-1.00) 
CA125 (35 U/mL cut-off)   0.80 (0.73-0.86) 0.69 (0.59-0.80) 0.89 (0.84-0.94) 0.71 (0.64-0.79) 0.68 (0.60-0.76) 0.91 (0.87-0.95) 
 463 
Abbreviations 464 
 465 
AC, Acylcarnitine 466 
CE, cholesterylester 467 
Cer, ceramide 468 
DAG, diacylglycerol 469 
Gb3, globotriasoylceramide 470 
Glc/GalCer, glucosyl/galactosylceramide 471 
LacCer, lactosylceramide 472 
LPC, lysophosphatidylcholine 473 
LPC O, alkyl-linked lysophosphatidylcholine 474 
LPC P, alkenyl-linked lysophosphatidylcholine 475 
LPE, lysophosphatidylethanolamine  476 
LPE O, alkyl-linked lysophosphatidylethanolamine 477 
LPE P, alkenyl-linked lysophosphatidylethanolamine 478 
PC, phosphatidylcholine 479 
PC O, alkyl-linked phosphatidylcholine 480 
PC P, alkenyl-linked phosphatidylcholine 481 
PE, phosphatidylethanolamine 482 
PE O, alkyl-linked phosphatidylethanolamine 483 
PE P, alkenyl-linked phosphatidylethanolamine 484 
PG, Phosphatidylglycerol 485 
PI, phosphatidylinositol 486 
S1P, sphingosine-1-phosphate  487 
SA1P, sphinganine-1-phosphate 488 
SM, sphingomyelin  489 
TAG, triacylglycerol 490 
 491 
 492 
Lipid class Number of lipids CV
AC 8 15 %
CE 21 24 %
Cer d16:1 8 26 %
Cer d18:0 7 36 %
Cer d18:1 9 25 %
Cer d18:2 9 27 %
Cer d20:1 4 22 %
DAG 18 29 %
Gb3 4 41 %
Glc/GalCer 22 29 %
LacCer 10 28 %
LPC 40 11 %
LPC P/LPC O 13 11 %
LPE 11 12 %
LPE P/LPE O 2 13 %
PC 70 20 %
PC P/PC O 46 23 %
PE 23 27 %
PE P/PE O 15 30 %
PG 4 23 %
PI 19 19 %
S1P/SA1P 4 9 %
SM 41 16 %
TAG 42 11 %
Supplementary Table S1. Number of lipids and the mean coefficient 
of variation (CV) for all the analyzed lipid classes.
Supplementary Table S2. Lipids that showed consistent alteration in all three and were significant in at least two study cohorts.
Lipid class Lipid name Change (%) p-value Change (%) p-value Change (%) p-value
CE 14:0 -10,5 0,113 -22,3 1,2E-05 -22,3 4,1E-06
CE 14:1 -13,0 0,247 -28,2 1,5E-04 -22,0 4,7E-05
CE 16:2 -11,8 0,060 -20,7 3,3E-04 -21,1 2,0E-07
CE 18:0 -9,8 0,113 -10,8 0,020 -26,7 4,9E-10
CE 18:2 -9,9 0,028 -2,1 0,568 -21,9 7,2E-10
Cer(d16:1/23:0) -7,0 0,300 -28,5 2,6E-06 -24,9 5,7E-04
Cer(d16:1/24:0) -17,7 0,027 -30,2 6,0E-07 -29,3 6,1E-08
Cer(d16:1/26:0) -15,7 0,055 -18,7 0,003 -17,1 0,004
Cer(d18:0/18:0) 36,1 0,001 45,0 0,044 49,7 5,7E-05
Cer(d18:0/20:0) 28,2 0,023 58,2 4,1E-04 22,0 0,018
Cer(d18:0/23:0) -8,8 0,158 -20,4 0,001 -17,4 0,004
Cer(d18:1/18:0) 56,2 2,9E-06 52,5 1,9E-04 71,4 7,2E-12
Cer(d18:1/20:0) 15,9 0,027 24,4 0,027 39,7 9,9E-08
Cer(d18:1/24:0) -4,4 0,570 -13,6 0,002 -11,9 0,009
Cer(d18:1/24:1) 18,8 0,003 6,9 0,477 30,5 1,1E-06
Cer(d18:2/18:0) 28,0 0,005 20,7 0,063 26,2 5,2E-04
Cer(d18:2/23:0) -10,9 0,190 -17,9 7,8E-04 -18,5 5,6E-04
Cer(d18:2/24:0) -13,4 0,105 -20,8 9,9E-05 -22,4 1,1E-05
Cer(d18:2/26:0) -10,7 0,298 -9,8 0,037 -14,2 0,040
Cer d20:1 Cer(d20:1/24:1) 29,1 6,8E-04 13,5 0,126 43,9 2,1E-07
DAG DAG(14:0/18:1) -24,0 0,203 -23,5 9,6E-04 -39,1 6,9E-04
Gb3 Gb3(d18:1/24:0) -16,8 0,011 -7,7 0,788 -23,1 8,6E-05
Glc/GalCer(d16:1/20:0) -21,6 0,011 -25,1 0,001 -16,8 9,7E-04
Glc/GalCer(d16:1/22:0) -19,0 0,015 -29,5 4,2E-05 -23,4 1,5E-05
Glc/GalCer(d16:1/23:0) -22,8 0,003 -22,5 0,008 -19,3 3,8E-04
Glc/GalCer(d16:1/24:0) -26,9 4,5E-04 -25,8 0,013 -23,1 5,0E-06
Glc/GalCer(d18:1/20:0) -15,4 0,019 -6,7 0,845 -19,7 9,2E-05
Glc/GalCer(d18:1/22:0) -18,8 0,001 -11,2 0,752 -25,9 2,6E-07
Glc/GalCer(d18:1/23:0) -19,4 0,003 -15,9 0,081 -23,8 7,8E-07
Glc/GalCer(d18:1/24:0) -17,2 0,002 -19,7 0,047 -24,2 4,7E-07
Glc/GalCer(d18:1/26:0) -16,3 0,016 -23,7 0,002 -21,0 9,4E-05
Glc/GalCer(d18:2/20:0) -19,9 0,003 -11,7 0,587 -23,3 1,7E-04
Glc/GalCer(d18:2/22:0) -19,2 0,002 -19,6 0,022 -17,9 5,0E-04
Glc/GalCer(d18:2/23:0) -22,2 0,003 -20,5 0,012 -21,6 5,2E-05
Glc/GalCer(d18:2/24:0) -17,1 0,002 -17,5 0,088 -23,9 4,8E-08
LacCer LacCer(d16:1/16:0) -3,9 0,495 -12,8 0,016 -21,1 5,3E-05
LPC 14:0_sn1 -31,2 1,9E-05 -13,7 0,001 -19,1 0,002
LPC 14:0_sn2 -34,0 3,1E-05 -21,0 3,4E-05 -30,3 2,3E-05
LPC 18:2_sn1 -32,0 1,1E-05 -5,0 0,147 -29,7 1,9E-07
LPC 18:2_sn2 -33,4 2,9E-06 -12,8 0,004 -34,7 2,3E-12
LPC 20:0_sn1 -24,5 6,2E-05 -2,7 0,308 -16,6 0,003
LPC 20:0_sn2 -25,2 9,9E-06 -6,9 0,085 -14,6 0,011
LPC 20:2_sn2 -25,4 6,7E-06 -7,0 0,067 -16,4 3,2E-05
LPC 20:3_sn2 -19,0 0,003 -2,6 0,226 -24,4 1,4E-06
LPC 22:0_sn1 -27,2 1,6E-07 -13,3 0,004 -28,7 6,3E-10
LPC 24:0_sn1 -21,0 3,4E-06 -10,0 0,015 -28,7 1,5E-12
LPC 24:0_sn2 -19,0 2,0E-05 -11,6 0,007 -28,9 2,3E-13
LPC O-20:0 -19,6 0,001 -6,0 0,095 -15,5 7,1E-04
LPC O-22:0 -15,6 0,007 -6,6 0,074 -25,3 4,8E-11
LPC O-22:1 -22,3 3,7E-04 -5,3 0,113 -17,5 0,002
LPC O-24:1 -15,3 0,019 -6,1 0,093 -17,8 8,2E-05
LPC O-24:2 -25,3 5,5E-05 -8,5 0,203 -33,0 1,2E-08
LPE 18:2_sn1 -37,7 5,8E-06 -1,3 0,288 -40,1 1,5E-11
LPE 18:2_sn2 -37,2 1,8E-06 -4,0 0,191 -35,4 4,6E-10
LPE P-16:0 -9,9 0,013 -23,3 1,5E-07 -12,4 0,197
LPE P-18:0 -13,2 0,005 -12,8 9,4E-05 -7,8 0,382
PC 28:0 -47,2 5,5E-06 -47,8 2,7E-07 -59,0 1,5E-15
PC 30:0 -26,4 0,001 -25,1 2,1E-05 -43,4 4,0E-15
PC 30:1 -39,4 2,1E-04 -34,6 1,2E-06 -52,1 2,4E-13
PC 30:2 -57,6 4,2E-08 -48,2 4,5E-07 -61,4 2,1E-14
Charité DiscoveryCharité Finland
LPC
LPC O
LPE
LPE P
PC
Glc/GalCer
CE
Cer d16:1
Cer d18:0
Cer d18:1
Cer d18:2
PC 31:1 -14,8 0,311 -23,8 0,002 -36,9 1,9E-08
PC 32:1 -12,2 0,795 -15,0 0,016 -29,0 1,9E-06
PC 32:2 -38,0 8,7E-07 -26,7 1,9E-06 -52,5 4,0E-19
PC 32:3 -42,9 1,1E-05 -34,3 2,9E-07 -58,5 4,2E-17
PC 33:2 -18,0 0,010 -7,8 0,098 -35,6 6,9E-13
PC 33:3 -23,3 0,021 -23,4 1,9E-04 -42,0 4,2E-11
PC 34:2 -15,9 0,001 -5,8 0,198 -28,6 4,5E-10
PC 34:3a -22,1 5,0E-04 -14,2 0,010 -37,9 9,7E-14
PC 34:3b -19,2 0,025 -17,5 0,001 -35,8 3,9E-12
PC 34:3c -25,4 0,002 -21,8 0,010 -44,1 1,2E-13
PC 34:4 -35,4 1,3E-05 -22,1 4,5E-05 -52,1 5,6E-16
PC 34:5 -28,0 0,006 -39,4 2,9E-08 -41,3 1,4E-05
PC 35:2a -16,5 0,036 -0,4 0,931 -26,3 2,6E-06
PC 35:2b -16,1 0,006 -2,9 0,413 -28,1 1,1E-09
PC 35:3a -26,7 1,3E-05 -5,9 0,151 -39,8 3,1E-15
PC 35:3b -17,1 0,019 -4,5 0,206 -35,9 2,0E-09
PC 36:1 -16,3 0,033 -9,5 0,038 -12,5 0,053
PC 36:2 -22,6 7,2E-05 -7,7 0,103 -35,1 2,0E-13
PC 36:3a -30,8 3,2E-07 -3,8 0,280 -36,0 2,2E-14
PC 36:3b -14,6 0,040 -4,9 0,186 -29,2 1,9E-08
PC 36:5a -16,9 0,030 -10,6 0,097 -32,1 1,4E-07
PC 36:6 -28,8 7,7E-04 -20,3 7,5E-04 -46,4 2,0E-09
PC 36:7 -32,8 9,3E-04 -52,7 1,6E-13 -27,4 2,1E-05
PC 37:1 -16,8 0,004 -5,1 0,300 -20,5 4,6E-06
PC 37:2 -26,5 2,6E-05 -11,7 0,022 -36,3 6,0E-13
PC 37:3 -13,5 0,031 -2,2 0,432 -30,4 7,4E-09
PC 38:0 -10,9 0,049 -5,9 0,106 -29,1 5,0E-11
PC 38:3 -19,4 0,007 -3,0 0,262 -30,6 1,5E-09
PC 38:5b -4,4 0,564 -19,6 0,002 -16,1 0,003
PC 38:6a -28,1 9,3E-05 -9,9 0,051 -35,0 2,6E-10
PC 38:6b -33,2 1,3E-06 -5,8 0,446 -38,0 7,1E-13
PC 40:8 -22,0 0,004 -7,7 0,051 -33,4 6,8E-10
PC P PC P-34:2 -29,8 2,3E-06 -12,7 0,035 -33,3 2,7E-13
PC O-32:1 -17,6 0,011 -3,4 0,490 -31,3 7,1E-10
PC O-34:1 -13,4 0,012 -0,2 0,968 -22,2 1,2E-08
PC O-34:2 -29,9 1,0E-05 -12,6 0,031 -39,7 6,7E-17
PC O-36:1 -10,2 0,075 -9,8 0,026 -27,6 1,5E-07
PC O-36:2b -27,1 4,4E-06 -2,1 0,924 -36,3 4,2E-14
PC O-36:3a -28,9 4,8E-07 -4,6 0,424 -38,7 4,8E-16
PC O-36:3b -22,1 1,5E-04 -0,2 0,644 -33,2 4,7E-13
PC P 36:2a -25,8 1,0E-04 -9,0 0,235 -26,8 6,2E-08
PC P-32:0 -17,6 0,001 -6,8 0,214 -20,2 8,1E-07
PC P-32:1 -16,2 0,018 -11,7 0,159 -21,4 1,6E-05
PC P-34:1 -13,8 0,039 -3,2 0,815 -13,9 3,6E-04
PE 34:3 -19,1 0,328 -19,5 0,009 -49,7 8,1E-07
PE 36:2 -10,7 0,326 -17,1 0,010 -37,9 1,5E-06
PE 36:3a -31,0 0,005 -3,9 0,359 -53,8 2,0E-07
PE 36:3b -44,6 0,003 -5,4 0,674 -54,7 3,9E-08
PE 36:5 -6,4 0,700 -25,9 4,1E-05 -26,5 0,023
PE 38:3 -9,7 0,583 -10,6 0,042 -40,4 6,8E-07
PE 38:5b -7,2 0,995 -23,5 1,0E-04 -36,9 1,6E-04
PE O-34:1 -25,6 3,8E-05 -11,7 0,030 -12,4 0,047
PE O-36:4 -35,9 1,3E-05 -2,6 0,148 -49,1 4,9E-11
PE O-38:5 -35,4 3,0E-06 -0,2 0,419 -38,5 1,3E-09
PE O-38:6 -22,7 0,001 -4,2 0,259 -16,2 0,044
PG 34:1 -2,6 0,870 -13,6 0,024 -22,9 0,011
PG 36:2 -5,5 0,740 -16,6 0,007 -25,6 3,5E-04
PI 32:0 -22,0 0,181 -19,6 0,005 -49,6 3,0E-04
PI 34:1 -18,7 0,050 -7,2 0,163 -31,3 4,7E-04
PI 34:2 -17,6 0,016 -4,1 0,371 -31,3 6,4E-06
PI 36:1 -30,7 4,1E-05 -16,7 0,001 -40,1 3,8E-07
PI 36:3a -42,8 1,4E-08 -1,9 0,195 -51,5 9,9E-10
PI 36:3b -27,7 2,1E-04 -3,8 0,223 -39,6 3,0E-09
PE
PE O
PG
PI
PC O
PI 38:2 -25,1 2,7E-04 -16,1 0,002 -40,5 3,5E-07
PI 38:3a -23,5 4,9E-04 -4,8 0,104 -33,8 1,6E-09
PI 38:3b -23,7 0,007 -3,9 0,458 -13,3 0,050
S1P d16:1 -10,2 0,045 -14,2 1,6E-04 -20,0 1,4E-08
S1P d18:1 -3,7 0,333 -9,3 0,001 -19,3 1,3E-07
S1P d18:2 -11,3 0,007 -2,0 0,396 -29,3 1,2E-13
SA1P SA1P d18:0 -6,4 0,126 -11,0 5,6E-04 -24,8 5,3E-13
SM 30:2 -29,3 1,2E-04 -24,5 2,5E-04 -35,8 2,2E-11
SM 31:1 -9,3 0,158 -11,3 0,033 -24,7 1,2E-07
SM 32:1 -3,4 0,615 -9,8 0,004 -17,3 7,4E-06
SM 32:2 -14,4 0,006 -13,7 9,7E-04 -28,0 3,3E-11
SM 36:0 27,8 0,012 40,0 0,008 6,9 0,288
SM 37:2 -24,7 4,2E-05 -9,5 0,069 -34,8 1,4E-13
SM 39:1 -8,9 0,203 -16,5 1,7E-04 -27,5 1,3E-10
SM 40:2b -10,0 0,044 -7,9 0,021 -27,3 4,5E-12
SM 44:2 12,6 0,035 13,1 0,041 5,0 0,304
TAG(14:0/16:0/18:1) -21,2 0,112 -31,0 6,4E-06 -37,3 1,0E-04
TAG(14:0/16:0/18:2) -16,3 0,318 -31,2 1,7E-05 -36,5 2,3E-04
TAG(14:0/16:1/18:1) -23,5 0,085 -30,4 1,1E-05 -44,3 1,5E-04
TAG(14:0/16:1/18:2) -28,1 0,009 -35,5 1,7E-05 -50,9 2,4E-06
TAG(14:0/17:0/18:1) -1,9 0,555 -20,4 0,004 -22,6 0,045
TAG(14:0/18:0/18:1) -17,5 0,166 -29,4 4,4E-05 -44,4 1,7E-04
TAG(14:0/18:2/18:2) -26,4 0,010 -23,0 0,013 -47,7 3,3E-06
TAG(14:1/16:0/18:1) -18,9 0,528 -30,3 1,9E-05 -35,4 0,005
TAG(14:1/16:1/18:0) -11,6 0,860 -23,7 0,001 -28,7 0,016
TAG(14:1/18:0/18:2) -12,7 0,391 -14,0 0,008 -25,3 0,014
TAG(14:1/18:1/18:1) -9,6 0,408 -15,7 0,009 -33,0 1,2E-04
TAG(16:0/18:1/18:1) 18,4 0,002 3,0 0,780 9,2 0,037
TAG(16:1/16:1/16:1) -19,3 0,207 -26,7 5,2E-04 -43,7 5,2E-05
TAG(16:1/16:1/18:0) -19,2 0,108 -27,6 2,5E-05 -40,5 6,6E-05
TAG(18:1/18:1/20:4) 30,3 0,003 40,5 9,7E-07 28,4 6,7E-06
TAG(18:1/18:1/22:6) 52,8 6,0E-04 28,6 0,004 54,9 5,4E-08
TAG
S1P
SM
